Registered title, quoted from ClinicalTrials.gov
Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07944651, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
3. Received at least one prior line of systemic therapy containing a covalent BTK-inhibitor.
Inclusion criterion 3
11.For females of child-bearing potential, two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax.
Inclusion criterion 17
2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib.
Exclusion criterion 2
3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug.
Exclusion criterion 3
4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed malignancy that has been controlled with curative-intent local treatment (surgery or other modalities).
Exclusion criterion 4
Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded.
Exclusion criterion 7
6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Inclusion criterion 6
Absolute neutrophil count (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing;
Inclusion criterion 8
Platelet count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing.
Inclusion criterion 9
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN);
Inclusion criterion 11
Total bilirubin ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted.
Inclusion criterion 12
Creatinine clearance ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or eGFR calculated using the Modification of Diet in Renal Disease [MDRD] formula);
Inclusion criterion 14
Serum creatinine ≤ 1.5 × ULN.
Inclusion criterion 15
10.International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
Inclusion criterion 16
5.Presence of at least one measurable lesion. Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable.
Inclusion criterion 5
6. Known human immunodeficiency virus (HIV) infection, or serology suggestive of active hepatitis B or hepatitis C infection, as follows:
Exclusion criterion 6
Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded.
Exclusion criterion 8
12.Females of child-bearing potential must agree to use two reliable contraceptive methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer).
Inclusion criterion 18
16. Pregnant or breastfeeding women.
Exclusion criterion 24
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07944651, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1.Histopathologically-confirmed mantle cell lymphoma (MCL) with documented t(11;14)(q13;q32) translocation and/or cyclin-D1 over-expression, accompanied by relevant biomarkers (e.g., CD5, CD19, CD20, or PAX5). All subjects must provide sufficient archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing.
- 2.Age ≥ 18 years, male or female.
- 3. Received at least one prior line of systemic therapy containing a covalent BTK-inhibitor.
- 4.Histopathologically-confirmed high-risk MCL, defined as meeting at least one of the following criteria: POD24, complex karyotype, TP53 mutation, del(17p), high-risk MIPI score, blastoid / pleomorphic variant, Ki-67 ≥ 30 %, bulky disease.
- 5.Presence of at least one measurable lesion. Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable.
- 6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- 7.Adequate hematological function:
- Absolute neutrophil count (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing;
- Platelet count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing.
- 8.Adequate hepatic function:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN);
- Total bilirubin ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted.
- 9.Adequate renal function:
- Creatinine clearance ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or eGFR calculated using the Modification of Diet in Renal Disease [MDRD] formula);
- Serum creatinine ≤ 1.5 × ULN.
- 10.International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- 11.For females of child-bearing potential, two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax.
- 12.Females of child-bearing potential must agree to use two reliable contraceptive methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer).
- 13.Estimated life expectancy > 3 months.
- 14.Capable of providing written informed consent, and able to understand and comply with study requirements.
Exclusion Criteria:
- 1. Current or suspected central nervous system (CNS) involvement of mantle cell lymphoma, or a prior history of CNS-involved disease.
- 2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib.
- 3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug.
- 4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed malignancy that has been controlled with curative-intent local treatment (surgery or other modalities).
- 5. Active, uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent signs/symptoms related to infection with no improvement despite appropriate antibiotic, antiviral, and/or other therapy).
- 6. Known human immunodeficiency virus (HIV) infection, or serology suggestive of active hepatitis B or hepatitis C infection, as follows:
- Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded.
- Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded.
- 7. Clinically significant cardiovascular disease, including:
- Myocardial infarction within 6 months before screening;
- Unstable angina within 3 months before screening;
- Clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
- QTcF (Fridericia correction) > 480 msec;
- History of second-degree type-II or third-degree atrioventricular (AV) block;
- New York Heart Association (NYHA) class III or IV congestive heart failure.
- 8. History of severe bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring transfusion or other medical intervention.
- 9. History of deep-vein thrombosis (DVT) or pulmonary embolism (PE) within the previous 12 months.
- 10. History of a major cerebrovascular event (including stroke or intracranial hemorrhage) within 6 months before the first dose of study drug.
- 11. Requiring ongoing treatment with strong or moderate CYP3A inhibitors or CYP3A inducers. Subjects who have received strong/moderate CYP3A inhibitors or inducers within 7 days (or less than 5 drug half-lives) before the first study-drug dose are excluded. Subjects receiving moderate CYP3A inhibitors may be considered for enrollment after a minimum 7-day wash-out period.
- 12. Requiring anticoagulation with warfarin or an equivalent vitamin-K antagonist (e.g., phenprocoumon) within 7 days of the first study-drug dose.
- 13. Active bleeding gastrointestinal ulcer, except cases attributable to mantle-cell lymphoma identified on endoscopy.
- 14. Known hypersensitivity to urate-lowering agents.
- 15. History of toxic epidermal necrolysis or Stevens-Johnson syndrome.
- 16. Pregnant or breastfeeding women.
- 17. Known hypersensitivity to any of the study drugs.
- 18. Any psychiatric or cognitive disorder that may limit the subject's ability to understand, provide informed consent, or comply with study requirements.
- 19. Subjects with active drug or alcohol abuse. Any life-threatening disease, medical condition, or organ-system dysfunction that, in the investigator's judgment, may jeopardize subject safety or introduce additional risks to participation in the study.
Quoted from ClinicalTrials.gov, NCT07944651, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07944651, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.